EGETIS THERAPEUTICS™

Interim Report January-September 2026

FDA approval of EMCITATE® (tiratricol) in the U.S. marks a transformative quarter for Egetis

Financial overview July-September

- Quarterly net revenue MSEK 21.5 (17.4), +24% at constant exchange rates (CER)
- Quarterly result MSEK -147.0 (-82.4)
- Cash flow for the quarter MSEK -111.9 (-57.2)
- Cash at the end of the quarter MSEK 266.5 (145.7)
- Earnings per share before and after dilution SEK -0.3 (-0.2)

Financial overview January-September

- Net revenue for the period MSEK 52.3 (44.6), +17% at CER
- Result for the period MSEK -350.4 (-222.8)
- Cash flow for the period MSEK 45.6 (-200.6)
- Cash at the end of the period MSEK 266.5 (145.7)
- Earnings per share before and after dilution SEK -0.8 (-0.6)

Significant events during the quarter

- FDA approved EMCITATE for treatment of peripheral thyrotoxicosis in patients with MCT8 deficiency in the U.S.
- Egetis RareLink™, the EMCITATE patient support program, was launched in partnership with PANTHERx® Rare
- A Rare Pediatric Disease Priority Review Voucher (PRV) was granted by FDA in connection with the approval of EMCITATE
- Tiratricol was granted Orphan Drug Designation for MCT8 deficiency in Japan
- Presented EMCITATE clinical data at the European Thyroid Association (ETA) and the European Society for Paediatric Endocrinology (ESPE) congresses, including data from the Triac Trial II and ReTRIACt studies
- Collaboration and supply agreement for EMCITATE signed with Orspec Pharma for Australia and New Zealand

Significant events after the quarter

- Largest retrospective study of tiratricol in RTH-beta, led by Erasmus Medical Center, was published, providing further scientific support for the continued development of tiratricol in this indication
- EMCITATE became commercially available in the U.S. for treatment of peripheral thyrotoxicosis in patients with MCT8 deficiency
- Egetis, and its subsidiary Rare Thyroid Therapeutics International AB (RTTI), entered into an agreement to sell the PRV for MUSD 190 (approximately MSEK 1,900). Former owners of RTTI are entitled to approximately 50 percent of net proceeds of the PRV

Financial overview

	2026 Jul-Sep	2025 Jul-Sep	2026 Jan-Sep	2025 Jan-Sep	2025 Jan-Dec
Net revenue, MSEK	21.5	17.4	52.3	44.6	62.4
Results after tax, MSEK	-147.0	-82.4	-350.4	-222.8	-342.5
Cash flow, MSEK	-111.9	-57.2	45.6	-200.6	-129.8
Cash, MSEK	266.5	145.7	266.5	145.7	215.8
Equity ratio, %	52	47	52	47	53
Earnings per share before dilution, SEK	-0.3	-0.2	-0.8	-0.6	-0.9
Earnings per share after dilution, SEK	-0.3	-0.2	-0.8	-0.6	-0.9
Average number of employees	60	40	52	40	40

©2026, Egetis Therapeutics. All rights reserved. Interim Report January-September 2026

EGETIS THERAPEUTICS™

Comments from the CEO

FDA approval of EMCITATE® in the U.S.

The third quarter was a defining period for Egetis, culminating on September 28 with FDA´s approval of EMCITATE for the treatment of peripheral thyrotoxicosis in patients with MCT8 deficiency. EMCITATE is the first and only approved treatment for patients with MCT8 deficiency in the U.S.

This is an achievement which I am immensely proud of. Above all, the approval represents an important milestone for patients living with MCT8 deficiency and their families, who until now have had no approved treatment option in the U.S. It also represents a transformational milestone for Egetis and marks the beginning of a new chapter as we transition fully into a commercial-stage rare disease company in the world's largest pharmaceutical market.

MCT8 deficiency is a devastating and life-limiting genetic disorder. Patients experience severe neurodevelopmental impairment combined with persistent peripheral thyrotoxicosis, and a median life expectancy of approximately 35 years. This underlines both the severity of the disease and the substantial unmet medical need that has motivated our work with EMCITATE.

The U.S. approval was supported by a comprehensive clinical development program, including ReTRIACt, Triac Trial I, Triac Trial II, the Erasmus Medical Center (EMC) Cohort Study and Survival Study, and the U.S. Expanded Access Program. I would once again like to thank the patients and families who participated in these studies, as well as the investigators, healthcare professionals, patient advocacy organizations, our collaborators and, of course, the entire Egetis team whose commitment made this achievement possible.

U.S. commercial launch of EMCITATE

With approval secured, our immediate priority has been to make EMCITATE available to eligible patients in the U.S. as quickly and efficiently as possible. I am proud to share that we initiated the U.S. launch on October 27, ahead of previously anticipated timelines. This achievement reflects the extensive commercial and operational preparations undertaken ahead of the FDA decision, enabling us to move rapidly following approval. We have already seen good traction among physicians for EMCITATE after the approval and the commercial availability announcements.

To support patients, caregivers and healthcare professionals from launch, we have implemented Egetis RareLink™, our dedicated patient support program for EMCITATE. Through Egetis RareLink, we have established the access infrastructure, including specialty distribution and dedicated support resources, designed to help patients, caregivers and healthcare professionals navigate the treatment journey. We have also partnered with PANTHERx® Rare to support medication access, education, care coordination and ongoing treatment services.

For an ultra-rare disease such as MCT8 deficiency, making a medicine commercially available is only one part of the challenge. Connecting diagnosed patients and their treating physicians with treatment and supporting them through the access process will be central to successful commercialization. Therefore, our objective extends beyond launching a medicine, to building an infrastructure capable of supporting the MCT8 deficiency community over the long term.

The FDA approval also resulted in Egetis receiving a Rare Pediatric Disease Priority Review Voucher, or PRV. On November 4, we entered into an agreement to sell the PRV for USD 190 million (approximately SEK 1.900 million). Former owners of Rare Thyroid Therapeutics International AB are entitled to approximately 50 percent of net proceeds of the PRV, as an earnout following Egetis' acquisition of EMCITATE® (tiratricol) in 2020.

Commercialization of EMCITATE in the EU and international markets

The revenue for EMCITATE during the third quarter was MSEK 21.5, a 24 percent increase at constant exchange rates (CER), compared with the same quarter in 2025. The majority of sales originate from Germany, the first and only country where we have concluded a national reimbursement process, with the German national statutory health insurers, GKV-Spitzenverband. In Spain, we had a first meeting with the Ministry of Health during the quarter, to discuss our submitted national pricing and reimbursement dossier for EMCITATE. In Italy and France, we await the publication of survival data for EMCITATE by Erasmus Medical Center, to strengthen our value dossiers.

EGETIS THERAPEUTICS™

Markets outside the U.S. and Europe

On August 31, we announced that our partner in Japan, Fujimoto Pharmaceutical Corporation, which holds an exclusive license to develop and commercialize EMCITATE for MCT8 deficiency in Japan, had been granted Orphan Drug Designation for tiratricol by Japan's Ministry of Health, Labor and Welfare. Among the benefits of this designation in Japan, a future marketing authorization application is eligible for Priority Review, reducing the review time from approximately twelve to nine months, and the market exclusivity period is extended to ten years. Tiratricol now holds Orphan Drug Designation for MCT8 deficiency in Japan, the U.S. and the EU. The NDA in Japan for EMCITATE is expected to be submitted in 2027.

Our distribution partner companies Er-Kim (Turkey, Central, Eastern, and Southeastern Europe) and taiba rare (Gulf region) are actively identifying patients in their respective territories and have initiated funded treatment to more patients. In the quarter we signed a collaboration and supply agreement with Orspec Pharma, to enable us to reach more patients with MCT8 deficiency in Australia and New Zealand.

Raising visibility of clinical evidence and awareness of MCT8 deficiency

We also continued to strengthen communication of the scientific evidence supporting tiratricol during the quarter. In September, clinical data relating to EMCITATE were presented at the 47th Annual Meeting of the European Thyroid Association (ETA) in Porto, Portugal, and the 64th Annual Meeting of the European Society for Paediatric Endocrinology (ESPE) in Marseille, France. The presentations included data from Triac Trial II examining early treatment in young pediatric patients with MCT8 deficiency and results from the ReTRIACt study evaluating the effects of tiratricol treatment withdrawal.

The continued presentations and publications of clinical evidence are important as awareness of MCT8 deficiency grows internationally. They support the medical community in understanding the disease and the role of tiratricol and provide an important scientific foundation as we work to broaden access to EMCITATE globally.

Exploring the potential of tiratricol in RTH-beta

Our work is also increasingly focused on the longer-term potential of tiratricol beyond MCT8 deficiency. Resistance to thyroid hormone beta (RTH-beta) is a separate indication from MCT8 deficiency, with no overlap between the patient populations, and tiratricol already holds Orphan Drug Designation for RTH-beta in both the U.S. and the EU. In October, the largest retrospective cohort study to date evaluating tiratricol in patients with RTH-beta, was published in eBioMedicine, a journal in the Lancet family. The international multicenter study, led by Erasmus Medical Center, included 28 patients aged from 0.4 to 73 years with 18 different THRB mutations. Median treatment duration was approximately four years. In this retrospective analysis, tiratricol was associated with statistically significant reductions in free thyroxine, or FT4, of 37 percent and thyroid stimulating hormone, or TSH, of 43 percent, together with a reduction in heart rate of 10 beats per minute.

These results further strengthen the scientific rationale for investigating tiratricol as a potential treatment for RTH-beta, a rare inherited thyroid hormone disorder for which there are currently no approved therapies. Tiratricol is investigational in RTH-beta and has not been approved by any regulatory authority for this indication.

We are continuing our work to finalize the development plan for tiratricol in RTH-beta. Scientific advisory boards have been convened, and preparations for regulatory interactions are ongoing. While MCT8 deficiency remains our immediate commercial focus, RTH-beta represents an opportunity to apply our growing expertise in rare thyroid hormone disorders to another patient population with significant unmet medical need.

Cash

We report cash of MSEK 267 (MSEK 146) as of September 30, 2026. The sale of the PRV will provide a significant non-dilutive cash contribution, strengthening our financial flexibility as we accelerate the commercialization of EMCITATE in the U.S. and advance the RTH-beta program.

EGETIS THERAPEUTICS™

Outlook

2026 is a year marked by several important milestones for Egetis. Our team focuses on delivering three key priorities:

- Successfully launch EMCITATE in the U.S.
- Optimize pricing and reimbursement and continue launch of EMCITATE in Europe
- Finalize the development plan for tiratricol in RTH-beta.

Stockholm, Sweden, November 5, 2026

Nicklas Westerholm
CEO

EGETIS THERAPEUTICS™

About Egetis Therapeutics

Egetis in brief

Egetis Therapeutics is a commercial-stage pharmaceutical company focused on developing and delivering innovative therapies for patients with rare diseases with significant unmet medical need. Combining scientific and clinical expertise with integrated late-stage development, regulatory and commercial capabilities and manufacturing expertise, Egetis is committed to delivering treatments and dedicated support to underserved patient communities.

The Company's lead product, EMCITATE® (tiratricol), is the first and only approved treatment of peripheral thyrotoxicosis in patients with MCT8 deficiency, a rare and life-shortening genetic disorder. EMCITATE holds marketing authorizations in the EU and in the U.S.


With headquarters in Stockholm, Sweden, and operations in the U.S. and EU, Egetis is building a sustainable global rare disease company.

About MCT8 deficiency

Monocarboxylate transporter 8 (MCT8) deficiency, also known as Allan–Herndon–Dudley syndrome (AHDS), is a rare, devastating, life-limiting, X-linked disorder caused by pathogenic mutations in the *SLC16A2* gene. These mutations impair the function of MCT8, a critical cell-surface thyroid hormone transporter responsible for thyroid hormone transport in specific cells, including in the brain. As a result, patients experience disrupted thyroid hormone signaling, characterized by insufficient thyroid hormone activity in the central nervous system and excessive exposure to the active thyroid hormone triiodothyronine (T3) in peripheral tissues. This leads to a complex disorder characterized by severe neurodevelopmental impairment and persistent peripheral thyrotoxicosis.

The elevated T3 concentrations in peripheral tissues can result in a chronic hypermetabolic state affecting multiple organs, including the heart, muscles, liver, and kidneys. Clinical manifestations may include failure to thrive, cardiovascular strain, muscle wasting, metabolic imbalance, and increased susceptibility to infections. These systemic consequences of persistent thyrotoxicosis are believed to contribute significantly to the increased morbidity and premature mortality associated with the disorder. Patients with MCT8 deficiency have a reported median life expectancy of approximately 35 years.

Pipeline Overview



[1] EMCITATE approved in the US on Sep 28, 2026. Launch initiated on Oct 27, 2026. [2] Launched in Germany in May 2025. [3] Preparations ongoing to submit NDA dossier in 2027, utilizing existing data generated from the global clinical development program.

MAA: Marketing Authorization Application; NDA: New Drug Application; MCT8: Monocarboxylate Transporter 8; RTH-beta: Resistance to Thyroid Hormone beta; FDA: U.S. Food and Drug Administration; EMA: European Medicines Agency; MHLW: Ministry of Health, Labor & Welfare (Japan); PRV: Priority Review Voucher; CEE: Central Eastern Europe; SEE: Southeastern Europe; ANZ: Australia & New Zealand; RoW: Rest of World.

EGETIS THERAPEUTICS™

About resistance to thyroid hormone beta

Resistance to Thyroid Hormone Beta (RTH-beta) is a rare inherited disorder caused by mutations in the THRB gene, leading to impaired thyroid hormone receptor beta (TR-beta) signaling. RTH-beta occurs equally in males and females. As a result of impaired TR-beta-mediated feedback regulation of the hypothalamic-pituitary-thyroid (HPT) axis, patients present with elevated circulating thyroid hormone levels, leading to clinical manifestations affecting multiple organ systems.

Patients with RTH-beta may present with goiter, as well as cardiovascular, metabolic, and neurocognitive manifestations. Recent evidence from independent patient cohort studies suggests increased cardiovascular morbidity in patients with RTH-beta. These studies report reduced life expectancy compared with the general population, with higher free thyroid hormone T4 (FT4) concentrations being associated with mortality and/or major cardiovascular events. The incidence of RTH-beta is estimated to be between 1 per 20,000-40,000 live births. There are currently no approved therapies for RTH-beta, representing a significant unmet medical need. Tiratricol has been granted Orphan Drug Designation for the treatment of RTH-beta in both the U.S. and EU.

For more information about Egetis Therapeutics, visit egetis.com and follow the Company on LinkedIn.
To learn more about MCT8 deficiency, please visit MCT8deficiency.com or www.lifewithmct8deficiency.com

EGETIS THERAPEUTICS™

Financial Information

Net revenue and results

Net revenue

Total net revenue for the quarter reached MSEK 21.5 (17.4), a 24 percent increase (24 percent increase at CER) compared to the same period last year, and a 24 percent increase compared to the previous quarter. Revenue consisted almost solely of EMCITATE® sales.

For the period January-September, total net revenue reached MSEK 52.3 (44.6), a 17 percent increase (17 percent increase at CER) compared to the same period last year.

During the period, the Group recognized revenue for reinvoiced costs to Solasia of MSEK 0.0 (0.1).

Cost of Goods Sold

Cost of Goods Sold amounted to MSEK -19.7 (-13.9) for the quarter and MSEK -47.1 (-36.3) for the period and is entirely attributable to EMCITATE. Apart from manufacturing and distribution costs the COGS line item includes the recurring depreciation of R&D and a one-time milestone of MSEK -4.0 (-) paid to EMC for the FDA approval of EMCITATE in the U.S. The R&D depreciation for the quarter and period amounted to MSEK -10.1 (-10.1) and MSEK -30.4 (-23.6), respectively. The depreciation of R&D will continue during EMCITATE's ten-year European orphan drug exclusivity period and corresponds currently to MSEK -3.4 per month. Depreciation has no impact on cash flow.

Operating expenses

Total operating expenses amounted to MSEK -136.9 (-80.0) for the quarter and MSEK -342.4 (-227.8) for the period.

Research and development expenses

Research and development expenses amounted to MSEK -26.6 (-33.0) for the quarter and MSEK -91.0 (-99.5) during the period. Costs were lower compared with the corresponding quarter and period in the previous year, primarily due to reduced clinical trial activities associated with the EMCITATE project.

Marketing and sales expenses

During the quarter, marketing and sales expenses amounted to MSEK -55.4 (-21.7) and during the period to MSEK -123.6 (-66.1). The increase in the quarter and the period is attributable to preparatory activities for the launch of EMCITATE in the U.S.

Administrative expenses

Administrative expenses amounted to MSEK -51.1 (-26.6) during the quarter and during the period to MSEK -119.3 (-65.4). The increase was primarily attributable to support activities required for the build-up of U.S. operations and costs related to the employee stock option programs (ESOP). ESOP costs, which have no impact on cash flow, will continue to vary with the development of the share price. During the period the ESOP costs amounted to MSEK -27.5 (-6.0).

Other operating income and operating expenses

Other operating income amounted to MSEK 1.8 (2.0) for the quarter and MSEK 8.0 (11.9) for the period, and other operating expenses amounted to MSEK -5.5 (-0.8) for the quarter and MSEK -16.5 (-8.7) for the period. The change is primarily explained by currency exchange rate fluctuations related to operating receivables and liabilities.

Net financial items

The net financial result amounted to MSEK -12.1 (-5.9) for the quarter and MSEK -13.2 (-3.2) for the period. The change compared to the same quarter and period of the previous year mainly consists of the revaluation of the lender's convertible right and unrealized exchange rate impact derived from foreign currency bank accounts and loans. The revaluation of the convertible right has no impact on cash flow and will continue to fluctuate with the development of the share price.

Tax

The total reported tax for the quarter amounted to MSEK -0.0 (-0.0) and MSEK -0.0 (-0.0) for the period and relates to the tax result in Egetis' subsidiary in the U.S.

Results

The result for the quarter amounted to MSEK -147.0 (-82.4) and to MSEK -350.4 (-222.8) for the period.

Earnings per share amounted to SEK -0.3 (-0.2) for the quarter and SEK -0.8 (-0.6) for the period, both before and after dilution.

Financial position

Cash

Cash as of September 30, 2026, amounted to MSEK 266.5 (145.7).

Cash flow

Cash flow from operating activities amounted to MSEK -100.5 (-49.1) for the quarter and to MSEK -258.8 (-174.2) for the period. Cash flow from operating activities is mainly driven by costs related to the preparations for the planned launch of EMCITATE in the U.S.

The cash flow from investing activities amounted to MSEK -2.3 (-) during the quarter and MSEK -5.0 (-2.8) during the period.

Cash flow from financing activities amounted to MSEK -9.1 (-8.2) during the quarter and MSEK 309.4 (-23.7) during the period and relate primarily to instalments paid on Group's borrowing and the share issue in April 2026.

Cash flow for the quarter amounted to MSEK -111.9 (-57.2) and MSEK 45.6 (-200.6) during the period.

Equity and equity ratio

Equity amounted to MSEK 340.2 (277.5) as of September 30, 2026. Equity per average number of shares amounted to SEK 0.8 (0.8) for the period. The Company's equity ratio was 52 (47) percent.

Liabilities and receivables

Long-term liabilities amounted to MSEK 21.9 (70.3) as of September 30, 2026. These consist of loans of MSEK - (16.9), convertible loans and convertible right of MSEK - (37.4), liabilities for leasehold rights MSEK 3.5 (6.3), deferred tax liability on leasehold rights MSEK 1.3 (1.9), and provisions for social charges related to the stock option programs of MSEK 17.1 (7.8).

Short-term liabilities amounted to MSEK 292.8 (247.4) and consisted mostly of other short-term and accrued liabilities of MSEK 206.4 (178.0), short-term portion of loans MSEK 18.7 (31.4), convertible loan and convertible right of MSEK 51.7 (-), and accounts payable MSEK 16.0 (37.9).

The change to short-term liabilities is primarily related to re-classification of the convertible loan and convertible right.

The increase in accrued liabilities is due to provisions for discounts determined annually. The provisions are estimated by the Company based on standard industry practices, with final adjustments to be made after finalizing pricing and reimbursement discussions with national authorities.

Investments in tangible and intangible assets

Intangible fixed assets amounted to MSEK 342.1 (383.6) as of September 30, 2026. No significant investments have been classified as tangible fixed assets during the period.

Shares

As of September 30, 2026, the number of ordinary shares in the company amounted to 464,965,562. The Company holds 25,863,043 C-shares in treasury as hedge for the active employee stock option programs. Total number of ordinary shares and C-shares is 490,828,605.

The number of shareholders amounted to 9,234 as of September 30, 2026. The 10 largest shareholders held 60.1 percent of the share capital. Egetis Therapeutics' shares are listed on the main list of Nasdaq Stockholm.

Stock option plan and warrant programs

Information regarding existing incentive programs

For information about current and previous employee stock option programs see note 7.

Employees

Number of employees amounted to 61 (40) individuals as of September 30, 2026, comprising 37 women and 24 men (25 women and 15 men).

Parent company

The parent company's revenue for the quarter amounted to MSEK 24.7 (22.2) and MSEK 74.0 (74.2) for the period. Revenue for the period consisted of billing for intra-group services from the parent company to the subsidiary companies: Rare Thyroid Therapeutics International AB (RTTI) and Egetis Therapeutics US Inc. totaling MSEK 57.9 (53.7), re-billing of costs for EMCITATE to RTTI totaling MSEK 16.1 (20.4) and re-billing to Solasia of MSEK 0.0 (0.1). The revenue decrease for the period mainly pertains to lower re-billing of costs for EMCITATE.

Operating expenses amounted to MSEK -60.5 (-41.0) for the quarter and MSEK -160.9 (-115.7) for the period. The increase in costs was primarily attributable to increased support activities required for the build-up of U.S. operations, as well as costs related to the employee stock option programs (ESOP), which will continue to vary with the development of the share price. The posting has no impact on cash flow. During the period the cost for the ESOP was MSEK -27.5 (-6.0). The parent company's result for the quarter amounted to MSEK -127.5 (-73.2) and MSEK -314.6 (-203.1) for the period.

Financial fixed assets amounted to MSEK 1 278.9 (437.5). Long-term loan liabilities amounted to MSEK - (16.9), convertible loans and convertible right to MSEK - (37.4), and other long-term liabilities to MSEK 17.1 (7.8).

Short-term loan liabilities amounted to MSEK 18.7 (31.4), convertible loans and convertible right to MSEK 51.7 (-), and other short-term liabilities, including accounts payable and intercompany liabilities, to MSEK 177.9 (161.9). The change in convertible loans and convertible right liabilities is due to the remaining term of the loan now being less than one year and therefore reported as a short-term liability.

A provision of MSEK 838.2 (–) has been recognized in the balance sheet in respect of the Company's contractual payment obligation arising upon the sale of the Company's Priority Review Voucher (PRV), as further described in Note 4. As a corresponding entry, the carrying amount of investments in group companies has been increased by the same amount, accounting for most of the increase in financial non-current assets. The provision reflects management's best estimate, as per September 30, 2026, of the expenditure required to settle the obligation.

EGETIS THERAPEUTICS™

Consolidated statement of income

MSEK	2026 Jul-Sep	2025 Jul-Sep	2026 Jan-Sep	2025 Jan-Sep	2025 Jan-Dec
Revenue	21,5	17,4	52,3	44,6	62,4
Costs of goods	-19,7	-13,9	-47,1	-36,3	-50,0
Gross profit	**1,9**	**3,5**	**5,2**	**8,2**	**12,4**
Research and development expenses	-26,6	-33,0	-91,0	-99,5	-158,3
Marketing and sales expenses	-55,4	-21,7	-123,6	-66,1	-97,3
Administrative expenses	-51,1	-26,6	-119,3	-65,4	-103,7
Other operating income	1,8	2,0	8,0	11,9	16,9
Other operating expense	-5,5	-0,8	-16,5	-8,7	-10,0
Operating expenses	**-136,9**	**-80,0**	**-342,4**	**-227,8**	**-352,4**
Operating result	**-135,0**	**-76,5**	**-337,2**	**-219,6**	**-339,9**
Financial items					
Finance income	5,3	1,0	13,6	9,0	13,3
Finance expense	-5,9	-4,1	-15,7	-18,2	-22,7
Revaluation of convertible right	-11,5	-2,8	-11,1	6,0	7,4
Sum financial items	**-12,1**	**-5,9**	**-13,2**	**-3,2**	**-2,1**
Results after financial net	**-147,0**	**-82,4**	**-350,4**	**-222,8**	**-342,1**
Tax	0,0	0,0	0,0	0,0	-0,4
Results after tax	**-147,0**	**-82,4**	**-350,4**	**-222,8**	**-342,5**
Share Data					
Number of outstanding shares at the end of period	464 965 562	359 238 126	464 965 562	359 238 126	395 162 672
Average number of outstanding shares during period	464 953 004	359 238 126	436 591 017	359 238 126	368 194 504
Average number of shares during period, after dilution	477 727 041	364 005 229	444 168 153	363 835 909	373 398 168
Earnings per share before dilution (SEK)	-0,3	-0,2	-0,8	-0,6	-0,9
Earnings per share after dilution (SEK)	-0,3	-0,2	-0,8	-0,6	-0,9
Equity per average number of outstanding shares (SEK)	0,7	0,8	0,8	0,8	0,9
Equity per average number of shares, after dilution (SEK)	0,7	0,8	0,8	0,8	0,9

MSEK	2026 Jul-Sep	2025 Jul-Sep	2026 Jan-Sep	2025 Jan-Sep	2025 Jan-Dec
Net loss for the period	**-147,0**	**-82,4**	**-350,4**	**-222,8**	**-342,5**
Translation exchange rate differences	-0,9	0,1	-1,3	-0,8	0,1
Comprehensive income for the period	**-147,9**	**-82,3**	**-351,7**	**-223,6**	**-342,5**

EGETIS THERAPEUTICS™

Consolidated statement of financial position

MSEK	09/30/2026	09/30/2025	12/31/2025
ASSETS			
Non-current assets			
Research and development costs	340.7	381.2	371.1
Licenses	1.4	2.4	2.2
Right-of-use assets	6.2	9.0	8.4
Deferred tax asset	1.3	1.9	1.7
Equipment	2.0	1.4	1.3
Financial non-current assets	3.2	0.8	0.8
Total non-current assets	**354.7**	**396.8**	**385.6**
Current assets			
Inventories	2.6	1.1	2.3
Accounts receivable	15.2	35.1	19.2
Other receivables	7.7	7.9	8.7
Prepaid expenses and accrued income	8.1	8.6	7.5
Cash and bank balance	266.5	145.7	215.8
Total current assets	**300.2**	**198.3**	**253.6**
Total assets	**654.9**	**595.1**	**639.1**

MSEK	09/30/2026	09/30/2025	12/31/2025
Equity			
Share capital	25.8	20.4	22.3
Other capital contributions	2,568.4	2,057.7	2,227.8
Reserves	45.8	33.2	36.8
Accumulated loss including net loss	-2,300.0	-1,833.9	-1,948.3
Total equity	**340.2**	**277.5**	**338.7**
Non-current liabilities			
Borrowing	-	54.3	45.0
Deferred tax liability	1.3	1.9	1.7
Other non-current liabilities	3.5	6.3	5.6
Provisions	17.1	7.8	7.2
Total non-current liabilities	**21.9**	**70.3**	**59.5**
Current liabilities			
Accounts payable	16.0	37.9	21.8
Current tax liabilities	-	-	0.1
Borrowing	70.4	31.4	31.5
Other liabilities	12.0	10.1	10.8
Accrued expenses and deferred income	194.4	167.9	176.7
Total current liabilities	**292.8**	**247.4**	**240.9**
Total equity and liabilities	**654.9**	**595.1**	**639.1**

EGETIS THERAPEUTICS™

Consolidated statement of cash flows

MSEK	2026 Jul-Sep	2025 Jul-Sep	2026 Jan-Sep	2025 Jan-Sep	2025 Jan-Dec
OPERATING ACTIVITIES					
Results after financial net	-147.0	-82.4	-350.4	-222.8	-342.1
Adjustments for non-cash items	41.1	22.0	72.6	30.7	49.1
Tax paid	0.0	0.0	-0.1	0.0	-0.5
Cash flow from operating activities before changes in working capital	**-105.9**	**-60.3**	**-277.8**	**-192.2**	**-293.5**
Cash flow from changes in working capital					
Increase/decrease in operating receivables	-15.3	-4.1	4.1	-23.5	-8.6
Increase/decrease in operating liabilities	20.7	15.4	14.9	41.5	35.0
Cash flow from changes in working capital	**5.4**	**11.3**	**19.1**	**18.0**	**26.4**
Cash flow from operating activities	**-100.5**	**-49.1**	**-258.8**	**-174.2**	**-267.0**
INVESTING ACTIVITIES					
Acquisition of subsidiaries, net cash	-	-	-1.7	-1.3	-1.3
Investment in financial assets	-2.3	-	-2.3	-	-
Purchase of property, plant and equipment	-	-	-1.0	-1.5	-1.5
Cash flow from investing activities	**-2.3**	**-**	**-5.0**	**-2.8**	**-2.8**
FINANCING ACTIVITIES					
New share issue	-	-	350.0	-	183.2
Costs new share issue	-	-	-18.9	-	-11.3
Transfer of own shares upon exercise of options	-	-	4.4	-	-
Repayment of loans	-8.2	-7.5	-23.6	-21.7	-29.3
Repayment of leases	-0.8	-0.7	-2.4	-2.0	-2.6
Cash flow from financing activities	**-9.1**	**-8.2**	**309.4**	**-23.7**	**140.0**
Cash flow for the period	**-111.9**	**-57.2**	**45.6**	**-200.6**	**-129.8**
Balance at beginning of period	378.4	202.6	215.8	351.0	351.0
Change in cash	-111.9	-57.2	45.6	-200.6	-129.8
Exchange rate difference in cash	0.1	0.3	5.1	-4.7	-5.4
CASH BALANCE AT THE END OF THE PERIOD	**266.5**	**145.7**	**266.5**	**145.7**	**215.8**

EGETIS THERAPEUTICS™

Consolidated statement of changes in equity

MSEK	Share capital	Other capital contributions	Accumulated loss incl. net results for the period	Other reserves	Total equity
Opening balance 01/01/2026	**22.3**	**2,227.8**	**-1,948.3**	**36.8**	**338.7**
Share issue	3.5	346.5	-	-	350.0
Costs, share issue	-	-18.9	-	-	-18.9
Comprehensive income for the period	-	-	-351.7	-	-351.7
Transactions with shareholders					
Sales of shares in own custody		4.4			4.4
Settlement of share-based stock option plan by employees		8.5		-8.5	-
Costs due to share-based payments of employee stock option	-	-	-	17.4	17.4
Closing balance 09/30/2026	**25.8**	**2,568.4**	**-2,300.0**	**45.8**	**340.2**
Opening balance 01/01/2025	**20.4**	**2,057.7**	**-1,610.1**	**24.8**	**492.9**
Share issue	1.9	181.3	-	-	183.2
Costs, share issue	-	-11.3	-	-	-11.3
Comprehensive income for the period	-	-	-342.5	-	-342.5
Transactions with shareholders					
Costs due to share-based payments of employee stock option	-	-	4.3	12.1	16.4
Closing balance 12/31/2025	**22.3**	**2,227.8**	**-1,948.3**	**36.8**	**338.7**

Change in share capital and number of shares

Event	Change in number of common shares	Change in number of C-shares	Change in share capital, SEK	Total number of shares	Total share capital, SEK
Opening balance 01/01/2026	**395,162,672**	**28,999,266**	**-**	**424,161,938**	**22,324,321**
Share issue 04/21/2026	66,666,667	-	3,508,773	490,828,605	25,833,094
Reclassification, 05/18/2026	3,117,885	-3,117,885	-	490,828,605	25,833,094
Reclassification, 09/02/2026	18,338	-18,338	-	490,828,605	25,833,094
Closing balance 09/30/2026	**464,965,562**	**25,863,043**	**3,508,773**	**490,828,605**	**25,833,094**

The issued C-shares were repurchased immediately after issuance and are held in treasury as of the balance sheet date. The purpose of holding the C-shares and the repurchase is to ensure future delivery of shares to participants in, as well as to cover any social costs for, the outstanding incentive programs. The C-shares will be converted into common shares before delivery to the participants in the programs.

Group's key ratios

The key ratios below are useful to those who read the financial statements and a complement to other performance targets in evaluating strategic investment implementation and the Group's ability to achieve financial goals and commitments.

MSEK	2026 Jan-Sep	2025 Jan-Sep	2025 Jan-Dec
Equity	340.2	277.5	338.7
Equity ratio %	52	47	53
Number of outstanding shares at the end of the period	464,965,562	359,238,126	395,162,672
Average number of outstanding shares during the period	436,591,017	359,238,126	368,194,504
Average number of shares during the period after dilution	444,168,153	363,835,909	373,398,168
Share Data*			
Earnings per share before dilution, SEK	-0.8	-0.6	-0.9
Earnings per share after dilution, SEK	-0.8	-0.6	-0.9
Cash flow from operating activities per average number of outstanding shares, SEK	-0.6	-0.5	-0.7
Equity per average number of outstanding shares, SEK	0.8	0.8	0.9
Equity per average number of shares after dilution, SEK	0.8	0.8	0.9
Dividend	-	-	-
Average number of employees	52	40	40

*Impact from dilution is not considered when result is negative.

Parent company - income statement

MSEK	2026 Jul-Sep	2025 Jul-Sep	2026 Jan-Sep	2025 Jan-Sep	2025 Jan-Dec
Revenue	24.7	22.2	74.0	74.2	102.2
Gross profit	**24.7**	**22.2**	**74.0**	**74.2**	**102.2**
Research and development expenses	-11.4	-8.0	-37.3	-30.0	-49.2
Marketing and sales expenses	-7.4	-7.5	-21.6	-25.3	-35.7
Administrative expenses	-41.7	-25.5	-102.1	-60.3	-95.8
Other operating income	0.3	0.0	0.9	0.5	0.6
Other operating expenses	-0.3	-0.1	-0.8	-0.6	-0.6
Operating expenses	**-60.5**	**-41.0**	**-160.9**	**-115.7**	**-180.7**
Operating result	**-35.8**	**-18.7**	**-86.9**	**-41.5**	**-78.6**
Financial items					
Finance income	3.9	1.0	8.0	9.0	13.1
Finance expense	-4.9	-3.7	-14.6	-17.5	-21.7
Revaluation of convertible right	-10.6	-2.8	-11.1	6.0	7.4
Total financial items	**-11.7**	**-5.5**	**-17.7**	**-2.6**	**-1.2**
Results after financial items	**-47.5**	**-24.2**	**-104.6**	**-44.1**	**-79.8**
Group contribution received/ given	-80.0	-49.0	-210.0	-159.0	-230.0
Results after tax	**-127.5**	**-73.2**	**-314.6**	**-203.1**	**-309.8**

Parent company - balance sheet

MSEK	09/30/2026	09/30/2025	12/31/2025
ASSETS			
Non-current assets			
Equipment	0.0	0.0	0.0
Financial non-current assets	1,278.9	437.5	438.0
Total non-current assets	**1,278.9**	**437.5**	**438.1**
Current assets			
Receivables from Group companies	1.3	1.0	2.1
Other receivables	0.1	0.5	0.4
Prepaid expenses and accrued income	7.4	8.0	7.1
Cash and bank balance	253.3	134.1	206.4
Total current assets	**262.1**	**143.6**	**216.0**
Total assets	**1,541.0**	**581.1**	**654.1**

MSEK	09/30/2026	09/30/2025	12/31/2025
Restricted equity			
Share capital	25.8	20.4	22.3
Non-restricted equity			
Share premium reserve	680.3	475.1	649.5
Reserves	45.8	33.2	36.8
Net loss for the period	-314.6	-203.1	-309.8
Total equity	**437.3**	**325.7**	**398.9**
Non-current liabilities			
Borrowing	-	54.3	45.0
Provisions	17.1	7.8	7.2
Total non-current liabilities	**17.1**	**62.1**	**52.2**
Current liabilities			
Liabilities to Group company	148.6	140.0	132.5
Accounts payable	5.2	5.4	7.8
Borrowing	70.4	31.4	31.5
Other liabilities	7.6	7.4	7.9
Provision	838.2	-	-
Accrued expenses and deferred income	16.5	9.2	23.3
Total current liabilities	**1,086.5**	**193.3**	**203.0**
Total equity and liabilities	**1,541.0**	**581.1**	**654.1**

EGETIS THERAPEUTICS™

Notes

Note 1 - Accounting principles

Egetis applies International Financial Reporting Standards (IFRS) as adopted by the EU. This report is prepared in accordance with IAS 34 Interim Financial Reporting and the Annual Accounts Act and should be read together with the Egetis consolidated financial statements for the year ended December 31, 2025. The Interim Report does not include all disclosures that would otherwise be required in a complete set of financial statements. Applied accounting principles and calculation methods are the same as in the 2025 Annual Report. Some amendments to existing standards became applicable from January 1, 2026, however none of these have a material impact on the consolidated financial statements or accounting policies. The parent company and the Group's reporting currency is SEK. All the numbers in this Interim Report are, unless otherwise stated, presented in million SEK. The preparation of Interim Reports requires certain critical accounting estimates to be made. Furthermore, Company management is required to make assessments when applying accounting principles.

See the Group's accounting principles in the 2025 Annual Report for more information on estimates and assessments.

Parent company

The parent company Egetis Therapeutics AB (publ) prepares financial reports in accordance with the Swedish Financial Reporting Board's recommendation RFR 2 Accounting for Legal Entities and the Swedish Annual Accounts Act. The parent company applies the exception from application of IFRS 16 Leases.

Operating risks

All business operations involve risk. Risks may be Company specific or due to events in the external environment and may affect a certain industry or market. The Group is, among others, exposed to the following operational and financial risks.

Operational risks - Pharmaceutical development, Manufacturing, Regulatory, Commercialization, Competition and Market Acceptance and Intellectual property.

Financial risks - Foreign currency, Need of working capital, General market risk, Credit and Interest rate risks.

A more detailed description of the Group's risk exposure is included in the 2025 Annual Report, Risks and Risk Management section and Note 3.

External risk factors

Egetis Therapeutics is dependent on the efficient and uninterrupted operation of various IT systems to run its business. A significant breakdown or other disruption in the IT systems (for example as a result of a virus attack or network congestion attacks) can affect the ability to conduct business in general and can lead to delays and increased costs in the Company's research and development work.

There is a risk that the Company as a result of, for example, viral pandemics, will not succeed in recruiting participants for its clinical studies, either because participants do not want, or due to restrictions should not, visit hospitals to avoid infection. There is also a risk that new variants of different microorganisms will lead to lockdowns in Sweden or in other countries, which could mean that the Company or its partners cannot conduct research and development work according to the existing clinical development plan. There is also a risk that caregivers need to allocate resources to meet the effects of different pandemics, which can lead to limited resources to participate in the Company's clinical trials.

Continued and/or escalating tension in the full-scale military invasion of Ukraine by Russia, the conflicts in the Middle East, a potential global tariff war led by the U.S. can ignite an inflationary situation in the society or result in global recession. These events could have a significant negative impact on the global macroeconomic situation and the Swedish economy. It could result in the Company or its partners not being able to conduct R&D efforts according to plan.

A more detailed description of the Group's risk exposure is included in the 2025 Annual Report, Risks and Risk Management section and Note 3.

EGETIS THERAPEUTICS™

Note 2 – Additional information

Other information in accordance with IAS 34.16A are found on the pages before the income statement and statement of comprehensive income. For information on earnings, cash flow and financial position, see pages 6-8. For significant events after the period, see page 1.

Note 3 – Segment reporting

The Group applies segment reporting with mainly two independent development areas, EMCITATE® and Aladote®.
The Company's highest executive responsible for resource allocation allocates the Company's resources between these two R&D projects. The Aladote project has been parked since June 2023. Revenue and expenses attributable to EMCITATE and Aladote are reported below.

2026 Jul-Sep MSEK	Emcitate	Aladote	Common	Sum
Revenue	21.5	0.0	-	**21.5**
Costs of sales of goods	-19.7	-	-	**-19.7**
Project costs	-41.8	-	-	**-41.8**
Other	-	-0.3	-94.8	**-95.2**
Operating results	**-40.0**	**-0.2**	**-94.8**	**-135.0**
Net financial items				**-12.1**
Pretax profit				**-147.0**

2025 Jul-Sep MSEK	Emcitate	Aladote	Common	Sum
Revenue	17.4	-	-	**17.4**
Costs of sales of goods	-13.9	-	-	**-13.9**
Project costs	-30.5	0.0	-	**-30.5**
Other	-	-	-49.5	**-49.5**
Operating results	**-27.0**	**0.0**	**-49.5**	**-76.5**
Net financial items				**-5.9**
Pretax profit				**-82.4**

2026 Jan-Sep MSEK	Emcitate	Aladote	Common	Sum
Revenue	52.2	-	-	**52.2**
Costs of sales of goods	-47.1	-	-	**-47.1**
Project costs	-104.7	-	-	**-104.7**
Other	-	-0.3	-237.4	**-237.7**
Operating results	**-99.5**	**-0.3**	**-237.4**	**-337.2**
Net financial items				**-13.2**
Pretax profit				**-350.4**

2025 Jan-Sep MSEK	Emcitate	Aladote	Common	Sum
Revenue	44.4	0.1	-	**44.6**
Costs of sales of goods	-36.3	-	-	**-36.3**
Project costs	-91.8	-0.1	-0.7	**-92.7**
Other	-	-	-135.2	**-135.2**
Operating results	**-83.7**	**0.0**	**-135.9**	**-219.6**
Net financial items				**-3.2**
Pretax profit				**-222.8**

2025 Jan-Dec MSEK	Emcitate	Aladote	Common	Sum
Revenue	62.3	0.1	0.0	**62.4**
Costs of sales of goods	-50.0	-	-	**-50.0**
Project costs	-138.0	-0.1	-0.7	**-138.9**
Other	-	-	-213.5	**-213.5**
Operating results	**-125.7**	**0.0**	**-214.2**	**-339.9**
Net financial items				**-2.1**
Pretax profit				**-342.1**

Turnover by type of revenue

MSEK	2026 Jul-Sep	2025 Jul-Sep	2026 Jan-Sep	2025 Jan-Sep	2025 Jan-Dec
Re-invoicing of costs to Solasia	0.0	-	0.0	0.1	0.1
Sales of goods	21.5	17.4	52.2	44.5	62.3
Total	**21.5**	**17.4**	**52.3**	**44.6**	**62.4**

Note 4 – Provisions and contingent liabilities

Egetis has a contractual obligation to pay the former owners of Rare Thyroid Therapeutics International AB and Erasmus Medical Center, the equivalent of 3 percent and 10 percent of the net sales of the product, respectively. In addition, the former owners are entitled to a one-time payment corresponding to approximately 50 percent of the net proceeds from the sale of a so-called U.S. Rare Pediatric Disease Priority Review Voucher (PRV). As of September 30, 2026, a provision of SEK 838.2 million has been recognized in respect of this obligation.

Note 5 – Related party transactions

Peder Walberg and Elisabeth Svanberg have been providing consultancy services to the Company, invoicing MSEK 1.6 and 0.8, respectively (0.2 and 1.4) during the period.

EGETIS THERAPEUTICS™

Note 6 – Borrowing

MSEK	09/30/2026	09/30/2025	12/31/2025
Convertible loan (excluding convertible right)	-32.4	-28.0	-28.2
Convertible right	-19.3	-9.4	-8.0
Borrowing - non-current	-	-16.9	-8.7
Borrowing - current	-18.7	-31.4	-31.5
Total	**-70.4**	**-85.7**	**-76.5**

A more detailed description of the borrowing and terms can be found in note 23 in the 2025 Annual Report.

The debt financing in euros is divided into two parts, 10 million euros ("Tranche A") and 15 million euros ("Tranche B"). Tranche A was utilized on November 30, 2023, and matures on April 1, 2027. The Tranche B drawdown window expired September 30, 2024, and was never utilized.

The interest rate for the tranches is based on the ECB's base rate (MRO) plus a margin. In accordance with the agreement, the FDA approval of EMCITATE will result in a reduction in the interest rate, effective from the fourth quarter of 2026.

Note 7 – Employee stock option plan

Egetis implements stock option plans for employees (ESOP) and key consultants. The options are granted to participants free of charge. The options have a three-year vesting period from the grant date, provided, with customary exceptions, that the participant is still employed by/providing services to Egetis. Once the options are vested, they can be exercised within a one-year period or a six-month period dependent on the terms of the respective ESOP. Each vested option entitles the holder to acquire one share in Egetis at a predetermined price, unless recalculation based on the terms and conditions has not been applied. The options have been valued at each grant date according to the Black-Scholes valuation model. For further information, see Note 11 in the 2025 Annual Report.

During September 2026, employees who had previously been granted options under the ESOP 2022/2026 employee stock option plan exercised 34,385 of the total 392,001 outstanding options to acquire shares in the Company. In addition, employees who had previously been granted options under the ESOP 2023/2026 employee stock option plan exercised 80,292 of the total 7,807,261 outstanding options to acquire shares in the Company.

During the second quarter of 2026, a new employee stock option plan, ESOP 2026/2029, was granted. The CEO and members of the management team (nine individuals) were granted 1,967,477 and 6,697,792 employee stock options, respectively. In addition to the plan, members of the Board of Directors were, in accordance with the resolution adopted at the Annual General Meeting, granted a total of 376,173 share rights.

During the third quarter and the first nine months of 2026, the average share price exceeded the exercise price of the ESOP-2022, 2025 and 2026 and the share rights why a dilution impact is reported in the number of shares after dilution. However, as earnings per share are negative, no dilution is reported in the key ratio earnings per share after dilution. As of September 30, 2026, the Company has five ESOPs outstanding. Full utilization of the granted employee stock options, the lender warrants and share rights would increase the number of shares in the Company by 42,779,134.

Changes in outstanding employee stock options and warrants to lenders during Jan-Sep 2026

	Option Plan 2026/2029	Option Plan 2025/2028	Option plan 2024/2027	Option plan 2023/2026	Option plan 2022/2026	Share rights 2026/2027	Share rights 2025/2026	Warrants to lender	Total number of outstanding options
Number of outstanding options 01/01/2026	**-**	**11,619,653**	**7,653,462**	**7,807,261**	**6,777,338**	**-**	**450,473**	**1,090,977**	**35,399,164**
Number of granted options during the period	12,717,728	880,000	-	-	-	376,173	-	-	**13,973,901**
Number of exercised options during the period	-	-	-	-	-6,419,722	-	-	-	**-6,500,014**
Number of forfeited options during the period	-18,838	-	-	-	-	-	-75,079	-	**-**
Number of outstanding options 09/30/2026	**12,698,890**	**12,499,653**	**7,653,462**	**7,726,969**	**357,616**	**376,173**	**375,394**	**1,090,977**	**42,779,134**

EGETIS THERAPEUTICS™

Note 8 – Key ratios definitions

Key performance measures defined in accordance with IFRS:

Earnings per share - Net income divided by average number of ordinary shares before dilution.
Number of shares at end of period - The number of outstanding ordinary shares before dilution at the end of the period.
Number of shares after dilution - The number of issued shares after dilution effect of potential shares at end of period. Outstanding stock options and warrants are only considered if they are "in the money".
Average number of shares during the period - Average number of outstanding ordinary shares before dilution for the period.
Average number of shares during the period after dilution - Average number of issued shares after dilution effect of potential shares. Outstanding stock options and warrants are only considered if they are "in the money".

Alternative performance measures (not defined under IFRS)

The Company defines the below ratios as follows:

Project costs - Refer to external costs that are directly attributable to the Group's costs regarding research and development of drug candidates.
Equity ratio, % - The period's closing equity divided by the period's closing balance sheet. The Company uses the alternative Equity ratio as it shows the proportion of total assets represented by shareholders' equity and has been included to allow investors to assess the Company's capital structure.
Cash flow from operations per share - Cash flow from operating activities divided by the average number of shares outstanding at the end of the period. The Company uses the alternative key figure Cash flow from operations per share because the Company believes that the key ratio gives investors a better understanding of the Company's cash flow in relation to its number of shares adjusted for changes in the number of shares outstanding during the period.

Equity per share - Equity divided by number of shares outstanding at the end of the period. Outstanding stock options and warrants are only considered if they are "in the money". The Company uses the alternative key ratio equity per share because the Company believes that the key ratio gives investors a better understanding of the historical return per share adjusted for changes in the number of shares outstanding during the period.

Number of employees (average) -The average number of employees at the end of each period.

		2026 Jan-Sep	2025 Jan-Sep	2025 Jan-Dec
A	Equity, MSEK	340.2	277.5	338.7
B	Balance sheet total, MSEK	654.9	595.1	639.1
A/B	**Equity ratio, %**	**52**	47	**53**
A	Net result, MSEK	-350.4	-222.8	-342.5
B	Equity, MSEK	340.2	277.5	338.7
A/B	**Return on equity, %**	**neg.**	neg.	**neg.**
A	Cash flow from operating activities, MSEK	-258.8	-174.2	-267.0
B	Average number of outstanding shares during the period, thousands	436,591	359,238	368,195
A/B	**Cash flow from operating activities per share, SEK**	**-0.6**	-0.5	**-0.7**
A	Equity, MSEK	340.2	277.5	338.7
B	Average number of outstanding shares during the period, thousands	436,591	359,238	368,195
A/B	**Equity per average number of shares before dilution, SEK**	**0.8**	0.8	**0.9**
A	Equity, MSEK	340.2	277.5	338.7
B	Average number of shares during the period after dilution, thousands	444,168	363,836	373,398
A/B	**Equity per average number of shares after dilution, SEK**	**0.8**	0.8	**0.9**

EGETIS THERAPEUTICS™

Other information

Financial calendar

Full Year Results 2026, February 25, 2027
Q1 Interim Report, April 29, 2027
Annual General Meeting, May 12, 2027
Q2 Interim Report, August 20, 2027
Q3 Interim Report, November 10, 2027

This report, and further information is available on the website www.egetis.com
This report has been reviewed by the Company's auditor. This is a translation of the Swedish Interim Report.

For further information contact:

Nicklas Westerholm, CEO
nicklas.westerholm@egetis.com

Yilmaz Mahshid, CFO
yilmaz.mahshid@egetis.com

Karl Hård, VP Investor Relations, Communications and Business Development
karl.hard@egetis.com

This information is such information that Egetis Therapeutics AB (publ) is obliged to disclose in accordance with the EU market abuse regulation. The information was submitted, through the above contact persons, for publication on November 5, 2026, at 7:30 am (CET).

Egetis Therapeutics AB (publ)
Klara Norra Kyrkogata 26, 111 22 Stockholm, Sweden
Org.nr. 556706-6724
Phone: +46(0)8-679 72 10
www.egetis.com

Analysts who follow Egetis Therapeutics

Cantor: Kristen Kluska & Ayan Hussein
DNB Carnegie: Arvid Necander & Erik Hultgård
Pareto Securities: Chien-Hsun Lee
Stifel: Clemence Thiers & Damien Choplain
Van Lanschot Kempen: Chiara Montironi

Forward-looking statements

This report contains forward-looking statements that reflect the company's current expectations. Although the company believes that the expectations reflected in such forward-looking statements are reasonable, no assurance can be given that such expectations will prove to be correct, as they are subject to risks and uncertainties that could cause actual results to differ materially from those expressed or implied by such statements.

Forward-looking statements speak only as of the date on which they are made and, other than as required by applicable law, the Company undertakes no obligation to update or revise them in light of new information, future events or otherwise.

Certification

This Interim Report for January-September 2026 provides a true and fair overview of the parent's and Group's business activities, financial position, and results of operations, and describes significant risks and uncertainties to which the companies in the Group are exposed.

Stockholm, November 5, 2026

Mats Blom

Chairman of the Board

Margarida Duarte

Board member

Gunilla Osswald

Board member

Birgitte Volck

Board member

Behshad Sheldon

Board member

Jay Donovan Wu

Board member

Nicklas Westerholm

CEO

EGETIS THERAPEUTICS™

Auditor's report

To the Board of directors in Egetis Therapeutics AB (publ), corporate identity number 556706-6724

Introduction

We have conducted a limited review of the condensed interim financial information (interim report) for Egetis Therapeutics AB (publ) as of September 30, 2026, and the nine-month period ending on that date. The board of directors and the managing director are responsible for preparing and presenting this interim report in accordance with IAS 34 and the Swedish Annual Accounts Act. Our responsibility is to express a conclusion on this interim report based on our limited review.

The focus and scope of the limited review

We have conducted our limited review in accordance with the International Standard on Review Engagements ISRE 2410, "Review of Interim Financial Information Performed by the Independent Auditor of the Entity." A limited review consists of making inquiries, primarily of persons responsible for financial and accounting matters, performing analytical procedures, and other review procedures. A limited review has a different focus and a significantly smaller scope compared to the focus and scope of an audit conducted in accordance with ISA and generally accepted auditing standards. The review procedures taken in a limited review do not enable us to obtain the assurance that we would become aware of all significant matters that might have been identified in an audit. Therefore, the conclusion expressed based on a limited review does not have the assurance that a conclusion expressed based on an audit has.

Conclusion

Based on our limited review, nothing has come to our attention that causes us to believe that the interim report is not, in all material respects, prepared for the group in accordance with IAS 34 and the Annual Accounts Act and for the parent company in accordance with the Annual Accounts Act.

Stockholm, November 5, 2026
Öhrlings PricewaterhouseCoopers AB

Niclas Bergenmo
Authorized Public Accountant

This is a translation of the Swedish language original. In the event of any differences between this translation and the Swedish language original, the latter shall prevail.